智通财经APP获悉，维亚生物(01873)午后涨近7%，截至发稿，涨6.42%，报2.82港元，成交额3455.01万港元。
消息面上，维亚生物近日发布中期业绩，收益8.32亿元人民币，同比减少15.27%；股东应占溢利1.22亿元，同比增加4.28%。公告称，集团毛利率为40.8%，相较于去年同期提升了6.3个百分点，这主要得益于朗华业务结构的优化调整以及CRO业务运营效率提升、新业务板块增长所带来的贡献。
国元国际此前指出，维亚生物自5年前已经布局AI制药，目前AI订单占比：AI相关订单占比达到新签订单的12%，且呈增长趋势。公司AIDD及CADD平台具备自研算法及平台建设的能力、拥有研发多种药物形态的经验、并且充分发挥了维亚基于结构的药物研发优势。在此基础之上，维亚正在从以计算方法为各个药物研发阶段赋能为主的阶段迈向以AI驱动药物设计，改变药物设计范式的新阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.